Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

420 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Australians with chronic lymphocytic leukaemia continue to have high rates of second primary malignancies in the modern era.
Baggio D, Chung E, Wellard C, Waters N, Cushion T, Chong G, Cochrane T, Cull G, Giri P, Hamad N, Johnston A, Lee D, Murali A, Morgan S, Mulligan S, Talaulikar D, Ratnasingam S, Wood E, Hawkes E, Opat S. Baggio D, et al. Among authors: waters n. Intern Med J. 2024 Jul;54(7):1223-1227. doi: 10.1111/imj.16445. Epub 2024 Jul 7. Intern Med J. 2024. PMID: 38973146
Sickle cell disease in Australia: a snapshot from the Australian Haemoglobinopathy Registry.
Nelson A, Ho PJ, Haysom H, Waters N, Wellard C, Chee M, Teo J, Greenway A, Mason K, Kidson-Gerber G, Kaplan Z, Carter T, Cole-Sinclair MF, Barbaro P, Wood EM; Haemoglobinopathy Registry investigators. Nelson A, et al. Among authors: waters n. Intern Med J. 2024 May;54(5):764-772. doi: 10.1111/imj.16297. Epub 2023 Dec 8. Intern Med J. 2024. PMID: 38064543
Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry.
Baggio D, Wellard C, Chung E, Talaulikar D, Keane C, Opat S, Giri P, Minson A, Cheah CY, Armytage T, Lee D, Chong G, Johnston A, Cochrane T, Waters N, Hamad N, Wood EM, Hawkes EA. Baggio D, et al. Among authors: waters n. Leuk Lymphoma. 2023 Mar;64(3):621-627. doi: 10.1080/10428194.2022.2157676. Epub 2022 Dec 21. Leuk Lymphoma. 2023. PMID: 38376128
Economic evaluation: immunoglobulin vs prophylactic antibiotics in hypogammaglobulinemia and hematological malignancies.
Carrillo de Albornoz S, Higgins AM, Petrie D, Irving A, Fanning L, Weinkove R, Crispin P, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey CO, Wood EM, McQuilten ZK. Carrillo de Albornoz S, et al. Among authors: waters n. Blood Adv. 2024 May 14;8(9):2259-2267. doi: 10.1182/bloodadvances.2023012047. Blood Adv. 2024. PMID: 38484199 Free PMC article.
Immunoglobulin replacement vs prophylactic antibiotics for hypogammaglobulinemia secondary to hematological malignancy.
McQuilten ZK, Weinkove R, Thao LTP, Crispin P, Degelia A, Dendle C, Gilbertson M, Johnston A, Keegan A, Pepperell D, Pullon H, Reynolds J, van Tonder T, Trotman J, Waters N, Wellard C, Weston H, Morrissey CO, Wood EM. McQuilten ZK, et al. Among authors: waters n. Blood Adv. 2024 Apr 9;8(7):1787-1795. doi: 10.1182/bloodadvances.2023011231. Blood Adv. 2024. PMID: 38592710 Free PMC article. Clinical Trial.
Developing and validating a discrete-event simulation model of multiple myeloma disease outcomes and treatment pathways using a national clinical registry.
Irving A, Petrie D, Harris A, Fanning L, Wood EM, Moore E, Wellard C, Waters N, Huynh K, Augustson B, Cook G, Gay F, McCaughan G, Mollee P, Spencer A, McQuilten ZK. Irving A, et al. Among authors: waters n. PLoS One. 2024 Aug 27;19(8):e0308812. doi: 10.1371/journal.pone.0308812. eCollection 2024. PLoS One. 2024. PMID: 39190684 Free PMC article.
420 results